106 related articles for article (PubMed ID: 32475305)
1. Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients.
Grani G; Zatelli MC; Alfò M; Montesano T; Torlontano M; Morelli S; Deandrea M; Antonelli A; Francese C; Ceresini G; Orlandi F; Maniglia CA; Bruno R; Monti S; Santaguida MG; Repaci A; Tallini G; Fugazzola L; Monzani F; Giubbini R; Rossetto R; Mian C; Crescenzi A; Tumino D; Pagano L; Pezzullo L; Lombardi CP; Arvat E; Petrone L; Castagna MG; Spiazzi G; Salvatore D; Meringolo D; Solaroli E; Monari F; Magri F; Triggiani V; Castello R; Piazza C; Rossi R; Ferraro Petrillo U; Filetti S; Durante C
Thyroid; 2021 Feb; 31(2):264-271. PubMed ID: 32475305
[No Abstract] [Full Text] [Related]
2. A Data-Driven Approach to Refine Predictions of Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study.
Grani G; Gentili M; Siciliano F; Albano D; Zilioli V; Morelli S; Puxeddu E; Zatelli MC; Gagliardi I; Piovesan A; Nervo A; Crocetti U; Massa M; Samà MT; Mele C; Deandrea M; Fugazzola L; Puligheddu B; Antonelli A; Rossetto R; D'Amore A; Ceresini G; Castello R; Solaroli E; Centanni M; Monti S; Magri F; Bruno R; Sparano C; Pezzullo L; Crescenzi A; Mian C; Tumino D; Repaci A; Castagna MG; Triggiani V; Porcelli T; Meringolo D; Locati L; Spiazzi G; Di Dalmazi G; Anagnostopoulos A; Leonardi S; Filetti S; Durante C
J Clin Endocrinol Metab; 2023 Jul; 108(8):1921-1928. PubMed ID: 36795619
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factors Improving ATA Risk System and Dynamic Risk Stratification in Low- and Intermediate-Risk DTC Patients.
Maino F; Botte M; Dalmiglio C; Valerio L; Brilli L; Trimarchi A; Mattii E; Cartocci A; Castagna MG
J Clin Endocrinol Metab; 2024 Feb; 109(3):722-729. PubMed ID: 37804529
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
J Clin Endocrinol Metab; 2020 Mar; 105(3):e457-65. PubMed ID: 31665318
[TBL] [Abstract][Full Text] [Related]
5. Modified dynamic risk stratification system further predicts individual outcome in patients with intermediate-risk papillary thyroid cancer.
Cuéllar DI; De Los Reyes A; Llamas-Olier A
Ann Endocrinol (Paris); 2023 Apr; 84(2):242-248. PubMed ID: 35483449
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Multicenter Study Examining the Relationship Between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis.
De Leo S; D'Elia S; Grani G; Dondi F; Bertagna F; Puxeddu E; Morelli S; Piovesan A; Nervo A; Zatelli MC; Gagliardi I; Samà MT; Aimaretti G; Crocetti U; Massa M; Deandrea M; Retta F; Pagano L; Rossi M; Solaroli E; Pezzullo L; Chiofalo MG; Pontecorvi A; Lombardi CP; Antonelli A; Patrizio A; Messuti I; Magri F; Spiazzi G; Ceresini G; Bruno R; Sparano C; Centanni M; Crescenzi A; Tallini G; Marotta V; Madeo B; Mian C; Filetti S; Durante C; Fugazzola L
Thyroid; 2023 Nov; 33(11):1318-1326. PubMed ID: 37725571
[No Abstract] [Full Text] [Related]
7. Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy.
Bojarsky M; Baran JA; Halada S; Isaza A; Zhuang H; States L; Grant FD; Robbins S; Sisko L; Ricarte-Filho JC; Kazahaya K; Adzick NS; Mostoufi-Moab S; Bauer AJ
J Clin Endocrinol Metab; 2023 Nov; 108(12):3338-3344. PubMed ID: 37265226
[TBL] [Abstract][Full Text] [Related]
8. ATA risk stratification in papillary thyroid microcarcinoma has low positive predictive value when identifying recurrence.
Tran A; Weigel RJ; Beck AC
Am J Surg; 2024 Mar; 229():106-110. PubMed ID: 37968147
[TBL] [Abstract][Full Text] [Related]
9. The American Thyroid Association risk stratification and long-term outcomes of differentiated thyroid cancer: a 20-year follow-up of patients in Saudi Arabia.
Jammah AA; AlSadhan IM; Alyusuf EY; Alajmi M; Alhamoudi A; Al-Sofiani ME
Front Endocrinol (Lausanne); 2023; 14():1256232. PubMed ID: 38047113
[TBL] [Abstract][Full Text] [Related]
10. Do radioiodine-avid lymph nodes from differentiated thyroid cancer on the initial posttherapy scan need repeated
Jiang Y; Liu S; Qiu X; Huo Y; Zhang X; Cai H; Lv Z; Ma C
Front Endocrinol (Lausanne); 2023; 14():1099449. PubMed ID: 37324259
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas.
Li G; Lei J; Song L; Jiang K; Wei T; Li Z; Gong R; Zhu J
Cancer Med; 2018 Nov; 7(11):5448-5456. PubMed ID: 30264548
[TBL] [Abstract][Full Text] [Related]
12. Differentiated Thyroid Cancers in Young Adults Versus Children: Clinical Characteristics and 10-year Follow-up Outcomes.
Satapathy S; Majeed AK; Ballal S; Bal C
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1670-e1677. PubMed ID: 37285485
[TBL] [Abstract][Full Text] [Related]
13. Effects of concomitant obesity and diabetes on the aggressiveness and outcomes of differentiated thyroid cancer patients.
Elbasan O; Yavuz DG
Arch Endocrinol Metab; 2021 Nov; 65(4):455-461. PubMed ID: 33909380
[TBL] [Abstract][Full Text] [Related]
14. Dynamic Risk Stratification Integrated with ATA Risk System for Predicting Long-Term Outcome in Papillary Thyroid Cancer.
Valerio L; Dalmiglio C; Maino F; Mattii E; Trimarchi A; Cartocci A; Castagna MG
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760625
[TBL] [Abstract][Full Text] [Related]
15. Impact factors of benefiting from initial 131 I ablation in patients with intermediate-risk differentiated thyroid carcinoma: a study based on a re-evaluation of therapeutic response.
Ren L; Hu Y; Hu Y; Xiao D; Sun J; Zhu B; Zhang C
Nucl Med Commun; 2024 Mar; 45(3):188-195. PubMed ID: 38165164
[TBL] [Abstract][Full Text] [Related]
16. Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer.
Gianoukakis AG; Choe JH; Bowles DW; Brose MS; Wirth LJ; Owonikoko T; Babajanyan S; Worden FP
Eur Thyroid J; 2024 Feb; 13(1):. PubMed ID: 38096102
[TBL] [Abstract][Full Text] [Related]
17. Prognostic of recurrence and survival in poorly differentiated thyroid cancer.
Hescot S; Al Ghuzlan A; Henry T; Sheikh-Alard H; Lamartina L; Borget I; Hadoux J; Baudin E; Dupuy C; Nikitski AV; Nikiforov YE; Schlumberger M; Nikiforova MN; Leboulleux S
Endocr Relat Cancer; 2022 Nov; 29(11):625-634. PubMed ID: 36040800
[TBL] [Abstract][Full Text] [Related]
18. Second radioiodine treatment in patients with differentiated thyroid carcinoma: Causes and effects.
Sicilia Pozo MLN; Pena Pardo FJ; Amo Salas M; Cruz Montijano M; Torres Hernández J; Padilla Bermejo A; Montalbán Méndez C; Zhao Montero M; Soriano Castrejón Á; García Vicente AM
Endocrinol Diabetes Nutr (Engl Ed); 2024 Jan; 71(1):4-11. PubMed ID: 38388076
[TBL] [Abstract][Full Text] [Related]
19. The effect of COVID-19 pandemic restrictions on the management of differentiated thyroid cancer in Turkey: a single tertiary centre experience.
Calapkulu M; Sencar ME; Ozturk Unsal I; Sakiz D; Tekinyildiz M; Ozbek M; Cakal E
Eur Arch Otorhinolaryngol; 2024 May; 281(5):2587-2595. PubMed ID: 38347198
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E Status and Stimulated Thyroglobulin at Ablation Time Increase Prognostic Value of American Thyroid Association Classification Systems for Persistent Disease in Differentiated Thyroid Carcinoma.
Repaci A; Vicennati V; Paccapelo A; Cavicchi O; Salituro N; Monari F; de Biase D; Tallini G; Altimari A; Gruppioni E; Fiorentino M; Pagotto U
Int J Endocrinol; 2019; 2019():3081497. PubMed ID: 31093278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
